Results overview: Found 2 records in 0.03 seconds.
Articles, 2 records found
Articles 2 records found  
1.
9 p, 341.6 KB Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study / Conteduca, V. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Wetterskog, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Sharabiani (Royal Marsden NHS Foundation Trust. Research Data Management and Statistics Unit) ; Grande, E. (Hospital Ramon y Cajal. Departamento de Oncologia Médica) ; Fernandez Perez, M. P. (Hospital Universitario Morales Meseguer. Departamento de Hematologia y de Oncologia Médica) ; Jayaram, A. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Salvi, S. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Castellano, D. (Hospital Universitario 12 de Octubre. Departamento de Oncologia Médica) ; Romanel, A. (Università di Trento. Centro di Biologia Integrata) ; Lolli, C. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Casadio, V. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Gurioli, G. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Amadori, D. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Font, A. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Vazquez Estevez, S. (, Hospital Universitario Lucus Augusti. Departamento de Oncologia Médica) ; González del Alba, A. (Hospital Universitario Son Espases Mallorca. Departament d'Oncologia Médica) ; Mellado, B. (IDIBAPS Hospital Clinic. Departament d'Oncologia Médica) ; Fernandez Calvo, O. (Hospital de Ourense. Departamento de Oncologia Médica) ; Méndez Vidal, M. J. (Hospital Universitario Reina Sofía. Departamento de Oncologia Médica) ; Climent, M. A. (Instituto Valenciano de Oncología) ; Duran, I. (Instituto de Biomedicina de Sevilla) ; Gallardo, E. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Rodriguez, A. (Hospital de León. Departamento de Oncologia Médica) ; Santander, C. (Hospital Universitario Miguel Servet. Departamento de Oncologia Médica) ; Sáez, M. I. (Hospital Regional y Hospital Virgen de la Victoria, Malaga. Departamento de Oncologia Médica) ; Puente, J. (Hospital Clínico San Carlos. Departamento de Oncologia Médica) ; Gasi Tandefelt, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Wingate, A. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Dearnaley, D. (Royal Marsden NHS Foundation Trust. Academic Urology Unit) ; Demichelis, F. (Università di Trento. Centro di Biologia Integrata) ; De Giorgi, U. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Gonzalez Billalabeitia, E. (Hospital Universitario Morales Meseguer. Departamento de Hematologia y de Oncologia Médica) ; Attard, G. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Spanish Oncology Genitourinary Group ; Universitat Autònoma de Barcelona
2632A>G (p. T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naı¨ve abiraterone-treated patients and were also associated with worse OS (HR 3. 26; 95% CI 1. 47-not reached; P¼0. [...]
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. [...]

2017
Annals of oncology, Núm. 28 (2017) , p. 1508-1516  
2.
10 p, 402.2 KB SEOM clinical guideline for treatment of kidney cancer (2017) / Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Méndez-Vidal, M. J. (Instituto Maimónides de Investigación Biomédica de Córdoba) ; Pérez-Gracia, J. L. (Clínica Universidad de Navarra) ; Sepúlveda-Sánchez, J. M. (Hospital Universitario 12 de Octubre) ; Campayo, M. (Hospital Universitari Mútua Terrassa) ; Chirivella-González, I. (Hospital Clínico, Valencia) ; García-del-Muro, X. (Institut d'Investigació Biomèdica de Bellvitge) ; González-del-Alba, A. (Hospital Universitario Son Espases) ; Grande, E. (Hospital Universitario Ramón y Cajal) ; Suárez, Cristina (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. [...]
2017 - 10.1007/s12094-017-1765-4
Clinical & Translational Oncology, Vol. 20 (november 2017) , p. 47-56  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.